Abstract:Intracellular accumulation of tau is a hallmark pathology in Alzheimer disease (AD) and the related tauopathies, thus targeting tau could be promising for drug development. Proteolysis Targeting Chimera (PROTAC) is a novel drug discovery strategy for selective protein degradation from within cells.Methods: A novel small-molecule PROTAC, named as C004019 with a molecular mass of 1,035.29 dalton, was designed to simultaneously recruite tau and E3-ligase (Vhl) and thus to selectively enhance ubiquitination and proteolysis of tau proteins. Western blotting, immunofluoresence and immunohistochemical staining were employed to verify the effects of C004019 in cell models (HEK293 and SH-SY5Y) and mouse models (hTau-transgenic and 3xTg-AD), respectively. The cognitive capacity of the mice was assessed by a suite of behavior experiments. Electrophysiology and Golgi staining were used to evaluate the synaptic plasticity.Results: C004019 induced a robust tau clearance via promoting its ubiquitination-proteasome-dependent proteolysis in HEK293 cells with stable or transient overexpression of human tau (hTau), and in SH-SY5Y that constitutively overexpress hTau. Furthermore, intracerebral ventricular infusion of C004019 induced a robust tau clearance in vivo. Most importantly, both single-dose and multiple-doses (once per 6 days for a total 5 times) subcutaneous administration of C004019 remarkably decreased tau levels in the brains of wild-type, hTau-transgenic and 3xTg-AD mice with improvement of synaptic and cognitive functions.Conclusions: The PROTAC (C004019) created in the current study can selectively and efficiently promote tau clearance both in vitro and in vivo, which provides a promising drug candidate for AD and the related tauopathies.

Discovery of Effective Dual PROTAC Degraders for Neurodegenerative Disease-Associated Aggregates

Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy

Discovery of Small-Molecule Degraders for Alpha-Synuclein Aggregates

Targeted Degradation of Alpha-Synuclein by Autophagosome-Anchoring Chimera Peptides.

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

PROTAC Technology for the Treatment of Alzheimer’s Disease: Advances and Perspectives

Recent advances of PROTACs technology in neurodegenerative diseases

Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?

Systemic Administration of Neurotransmitter-Derived Lipidoids-PROTACs-DNA Nanocomplex Promotes Tau Clearance and Cognitive Recovery for Alzheimer's Disease Therapy

Selective Degradation of Hyperphosphorylated Tau by Proteolysis-Targeting Chimeras Ameliorates Cognitive Function in Alzheimer’s Disease Model Mice

Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer's disease model mice

Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera

Design, Synthesis and Biological Evaluation of α-Synuclein Proteolysis-Targeting Chimeras

Chemical-Mediated Targeted Protein Degradation in Neurodegenerative Diseases

Aggregate-selective removal of pathological tau by clustering-activated degraders

A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models

Development of small molecules for disrupting pathological amyloid aggregation in neurodegenerative diseases

Targeting protein aggregation: the promising application of polyoxometalates in neurodegenerative diseases

A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies

Generation of Tau Dephosphorylation-Targeting Chimeras for the Treatment of Alzheimer’s Disease and Related Tauopathies

Generation of tau dephosphorylation-targeting chimeras for the treatment of Alzheimer's disease and related tauopathies